Risk for intracranial hemorrhage after tissue plasminogen activator treatment for acute myocardial infarction

Annals of Internal Medicine

Volumn 129, Issue 8, 1998, Pages 597-604

  Gurwitz, Jerry H ^a   Gore, Joel M ^b   Goldberg, Robert J ^b   Barron, Hal V ^c   Breen, Timothy ^c   Rundle, Amy Chen ^c   Sloan, Michael A ^d   French, William ^e   Rogers, William J ^f  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MASSACHUSETTS   (United States)

^c GENENTECH INC   (United States)

^d Harbin Clinic   (United States)

^e HARBOR UCLA MEDICAL CENTER   (United States)

^f UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

STREPTOKINASE; TISSUE PLASMINOGEN ACTIVATOR;

ACUTE HEART INFARCTION; ADULT; AGED; ARTICLE; BRAIN HEMORRHAGE; BRAIN SCINTISCANNING; COMPUTER ASSISTED TOMOGRAPHY; DOSE RESPONSE; FEMALE; FIBRINOLYTIC THERAPY; HUMAN; MAJOR CLINICAL STUDY; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; RISK ASSESSMENT;

EID: 0032532396     PISSN: 00034819     EISSN: None     Source Type: Journal    
DOI: 10.7326/0003-4819-129-8-199810150-00002     Document Type: Article

References (17)

1. Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients. Fibrinolytic Therapy Trialists' (FTT) Collaborative Group. Lancet. 1994;343:311-22.
2. Gore JM, Granger CB, Simoons ML, Sloan NA, Weaver WD, White HD, et al. Stroke after thrombolysis. Mortality and functional outcomes in the GUSTO-I trial. Global Use of Strategies to Open Occluded Coronary Artery. Circulation. 1995;92:2811-8.
3. Krumholz HM, Murillo JE, Chen J, Vaccarino V, Radford MJ, Ellerbeck EF, et al. Thrombolytic therapy for eligible elderly patients with acute myocardial infarction. JAMA. 1997;277:1683-8.
4. Gurwitz JH, Goldberg RJ. Coronary thrombolysis for the elderly. Is clinical practice really lagging behind evidence of benefit? JAMA. 1997;277:1723-4.
5. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. The GUSTO investigators. N Engl J Med. 1993; 329:673-82.
6. Simoons ML, Maggioni AP, Knatterud G, Leimburger JD, de Jaegere P, van Domburg R, et al. Individual risk assessment for intracranial haemorrhage during thrombolytic therapy. Lancet. 1993;342:1523-8.
7. Gore JM, Sloan M, Price TR, Randall AM, Bovill E, Collen D, et al. Intracerebral hemorrhage, cerebral infarction, and subdural hematoma after acute myocardial infarction and thrombolytic therapy in the Thrombolysis in Myocardial Infarction Study: Thrombolysis in Myocardial Infarction, Phase II, pilot and clinical trial. Circulation. 1991;83:448-59.
8. Maggioni AP, Franzosi MG, Santoro E, White H, Van de Werf F, Tognoni G. The risk of stroke in patients with acute myocardial infarction after thrombolytic and antithrombotic treatment. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico II (GISSI-2), and The International Study Group. N Engl J Med. 1992;327:1-6.
9. Gurwitz JH, Col NF, Avorn J. The exclusion of the elderly and women from clinical trials in acute myocardial infarction. JAMA. 1992;268:1417-22.
10. Killip T 3d, Kimball JT. Treatment of myocardial infarction in a coronary care unit. A two year experience with 250 patients. Am J Cardiol. 1967;20:457-64.
11. Physicians' Desk Reference. Montvale, NJ: Medical Economics; 1997.
12. Hosmer DW, Lemeshow S. Applied Logistic Regression. New York: Wiley; 1989.
13. Hanley J, McNeil BJ. The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology. 1982;143:29-36.
14. Becker RC, Gore JM, Rubison M, Becker RC, Gore JM, Lambrew C, et al. Association between body weight and in-hospital clinical outcome following thrombolytic therapy: a report from the National Registry of Myocardial Infarction. Journal of Thrombosis and Thrombolysis. 1995;2:231-7.
15. White HD, Barbash GI, Modan M, Simes J, Diaz R, Hampton JR, et al. After correcting for worse baseline characteristics, women treated with thrombolytic therapy for acute myocardial infarction have the same mortality and morbidity as men except for a higher incidence of hemorrhagic stroke. Investigators of the International Tissue Plasminogen Activator/Streptokinase Mortality Study. Circulation. 1993;88(5 Pt 1):2097-103.
16. Berkowitz SD, Granger CB, Pieper KS, Lee KL, Gore JM, Simoons M, et al. Incidence and predictors of bleeding after contemporary thrombolytic therapy for myocardial infarction. The Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries (GUSTO) I Investigators. Circulation. 1997;95:2508-16.
17. A clinical trial comparing primary coronary angioplasty with tissue plasminogen activator for acute myocardial infarction. The Global Use of Strategies to Open Occluded Coronary Arteries in Acute Coronary Syndromes (GUSTO llb) Angioplasty Substudy Investigators. N Engl J Med. 1997;336:1621-8.